These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 16093991)

  • 21. Risk of fracture after androgen deprivation for prostate cancer.
    Shahinian VB; Kuo YF; Freeman JL; Goodwin JS
    N Engl J Med; 2005 Jan; 352(2):154-64. PubMed ID: 15647578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Osteoporosis in castration therapy--a neglected field].
    Bratt O; Akesson K
    Lakartidningen; 2011 Sep 28-Oct 4; 108(39):1902-5. PubMed ID: 22111227
    [No Abstract]   [Full Text] [Related]  

  • 23. [Osteoporosis due to androgen suppression therapy in men with prostate cancer].
    Roux C
    Prog Urol; 2003 Apr; 13(2 Suppl 1):24-7. PubMed ID: 12815806
    [No Abstract]   [Full Text] [Related]  

  • 24. Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy.
    Bernat MM; Pasini J; Mareković Z
    Coll Antropol; 2005 Dec; 29(2):589-91. PubMed ID: 16417166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies.
    Dalla Volta A; Mazziotti G; Maffezzoni F; Grisanti S; Palumbo C; Pedersini R; Maroldi R; Berruti A
    J Clin Oncol; 2020 Oct; 38(29):3363-3366. PubMed ID: 32603244
    [No Abstract]   [Full Text] [Related]  

  • 26. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.
    Smith MR; Lee WC; Brandman J; Wang Q; Botteman M; Pashos CL
    J Clin Oncol; 2005 Nov; 23(31):7897-903. PubMed ID: 16258089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.
    Shao YH; Moore DF; Shih W; Lin Y; Jang TL; Lu-Yao GL
    BJU Int; 2013 May; 111(5):745-52. PubMed ID: 23331464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen deprivation therapy for prostate cancer.
    Bahnson R
    J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
    [No Abstract]   [Full Text] [Related]  

  • 30. More should be done to prevent the harmful effects of long-term androgen ablation therapy in prostate cancer.
    Barrass BJ; Thurairaja R; Persad RA
    BJU Int; 2004 Jun; 93(9):1175-6. PubMed ID: 15180599
    [No Abstract]   [Full Text] [Related]  

  • 31. Prostate cancer: Bone density testing--essential or extraneous?
    Yu EY
    Nat Rev Urol; 2013 Jan; 10(1):11-2. PubMed ID: 23229500
    [No Abstract]   [Full Text] [Related]  

  • 32. Degarelix (firmagon) for prostate cancer.
    Med Lett Drugs Ther; 2009 Oct; 51(1323):82-3. PubMed ID: 19838145
    [No Abstract]   [Full Text] [Related]  

  • 33. Long term androgen deprivation therapy in prostate cancer.
    Ockrim JL; Abel PD
    BMJ; 2008 Sep; 337():a1361. PubMed ID: 18809586
    [No Abstract]   [Full Text] [Related]  

  • 34. Re: Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer.
    Miró C; De Cobelli O; Orecchia R; Sancho G; Villavicencio H; Craven-Bartle J
    J Urol; 2002 Aug; 168(2):662-3; author reply 663. PubMed ID: 12131341
    [No Abstract]   [Full Text] [Related]  

  • 35. Calcium supplements in patients with prostate cancer.
    Molokwu CN
    BJU Int; 2007 Dec; 100(6):1411. PubMed ID: 17979937
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.
    J Support Oncol; 2006 Feb; 4(2):99-100. PubMed ID: 16499137
    [No Abstract]   [Full Text] [Related]  

  • 38. Controversies surrounding hormonal deprivation.
    Denis LJ
    Acta Urol Belg; 1996 May; 64(2):81-4. PubMed ID: 8701819
    [No Abstract]   [Full Text] [Related]  

  • 39. [Androgen deprivation therapy for prostate cancer and osteoporotic risk].
    Cortet B; Lartigau E; Caty A; Moulinier F; Staerman F; Villamizar-Vesga J; Villers A
    Prog Urol; 2012 Sep; 22 Suppl 2():S31-8. PubMed ID: 23098788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re: Diethylstilbesterol revisited: androgen deprivation, osteoporosis an prostate cancer.
    Pitts WR
    J Urol; 2002 Jul; 168(1):201; author reply 201. PubMed ID: 12050534
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.